Natera

Natera

Genetic testing and diagnostics solutions

About

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care through precise genetic insights.

Company Stage

IPO

Employees

1,001-5,000

Industries

Biotechnology, Healthcare

Total Funding

$149.9M

Headquarters

N/A

Founded

2004


Simplify Jobs

Simplify's Take

What believers are saying

  • Natera's continuous innovation, such as the launch of the Prospera Heart test with DQS, demonstrates its commitment to improving patient outcomes and maintaining market leadership.
  • The company's diverse product offerings across oncology, transplant health, and women's health provide multiple revenue streams and reduce dependency on a single market.
  • Significant investments from entities like Massachusetts Financial Services Co. MA indicate strong financial backing and confidence in Natera's growth potential.

What critics are saying

  • Allegations of deceptive sales and billing practices could damage Natera's reputation and lead to legal and financial repercussions.
  • The highly competitive nature of the genetic testing market requires constant innovation and differentiation to maintain market share.

What makes Natera unique

  • Natera's focus on cell-free DNA (cfDNA) technology for a wide range of applications, from oncology to prenatal screening, sets it apart from competitors who may specialize in only one area.
  • The introduction of unique features like the Donor Quantity Score (DQS) for transplant rejection detection enhances the accuracy and reliability of their tests, distinguishing them from other genetic testing companies.
  • Natera's extensive portfolio of over 200 peer-reviewed publications underscores its commitment to scientific validation and credibility, which is a significant competitive advantage.

Help us improve and share your feedback! Did you find this helpful?


Growth & Insights
Headcount

6 month growth

8%

1 year growth

24%

2 year growth

61%

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Recently Posted Jobs

Sign up to get curated job recommendations

Natera is Hiring for 0 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Natera's jobs every 8 hours, so check again soon! Browse all jobs →